Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALON extension study of brolucizumab treat-to-control dosing in neovascular age-related macular degeneration
MOH_2021-02-01_009708Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brolucizumab in exudative macular degeneration, sponsored by Novartis. Started Dec 2020; status: active, not recruiting.
02
Drugs
brolucizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-02-01_009708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-01_009708.